{
    "name": "vitamin A",
    "comment": "OTC",
    "other_names": [
        "Retinol",
        "Aquasol A",
        "retinyl acetate",
        "retinyl palmitate"
    ],
    "classes": [
        "Vitamins",
        "Fat-Soluble"
    ],
    "source": "https://reference.medscape.com/drug/retinol-aquasol-a-vitamina-344426",
    "pregnancy": {
        "common": [
            "Pregnancy Category: A (oral); C (doses exceeding RDA); X (>6,000 units/day administered parenterally)",
            "Lactation: Distributed into milk; safe at RDA levels"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Distributed into milk; safe at RDA levels"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "IV use",
                "Hypervitaminosis A",
                "Malabasorption syndrome (oral therapy)",
                "Pregnancy (dose >RDA)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution if dose >25,000 units/day (monitor closely)",
                "Evaluate additional vitamin deficiencies if diagnosis of vitamin deficiency occurs (single vitamin A deficiency rare)",
                "Caution in renal impairment (toxicity reported)",
                "Monitor prolonged administration over 25,000 units/day; take into account vitamin intake from other dietary and supplement sources",
                "Efficacy of large systemic doses of 100,000 to 300,000 units/day vitamin A for the treatment of acne not established"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "vitamin A and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "vitamin A, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beta carotene",
            "description": {
                "common": "vitamin A, beta carotene.\nEither increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Administration of beta-carotene with vitamin A usually is not necessary and should be avoided to prevent the development of hypervitaminosis A."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bexarotene",
            "description": {
                "common": "bexarotene increases toxicity of vitamin A by pharmacodynamic synergism. Use Caution/Monitor. (Vitamin A) Additive retinoid effects. Avoid consuming vitamin-A containing supplements in amounts exceeding FDA recommended daily allowance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide, vitamin A.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etretinate",
            "description": {
                "common": "etretinate increases toxicity of vitamin A by pharmacodynamic synergism. Use Caution/Monitor. (Vitamin A) Additive retinoid effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "isotretinoin increases toxicity of vitamin A by pharmacodynamic synergism. Use Caution/Monitor. (Vitamin A) Additive retinoid effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, vitamin A.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "vitamin A increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acitretin",
            "description": {
                "common": "acitretin increases toxicity of vitamin A by pharmacodynamic synergism. Minor/Significance Unknown. (Vitamin A) Additive retinoid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "busulfan",
            "description": {
                "common": "vitamin A, busulfan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "capecitabine",
            "description": {
                "common": "vitamin A, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carboplatin",
            "description": {
                "common": "vitamin A, carboplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carmustine",
            "description": {
                "common": "vitamin A, carmustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chitosan",
            "description": {
                "common": "chitosan decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "vitamin A, chlorambucil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. (Vitamin A)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cisplatin",
            "description": {
                "common": "vitamin A, cisplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cladribine",
            "description": {
                "common": "vitamin A, cladribine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. (Vitamin A)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cytarabine",
            "description": {
                "common": "vitamin A, cytarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "vitamin A, dacarbazine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "decitabine",
            "description": {
                "common": "vitamin A, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "docetaxel",
            "description": {
                "common": "vitamin A, docetaxel. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "floxuridine",
            "description": {
                "common": "vitamin A, floxuridine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludarabine",
            "description": {
                "common": "vitamin A, fludarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "vitamin A, fluorouracil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "vitamin A, gemcitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "vitamin A, ifosfamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan",
            "description": {
                "common": "vitamin A, irinotecan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "vitamin A, irinotecan liposomal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lomustine",
            "description": {
                "common": "vitamin A, lomustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "vitamin A, mechlorethamine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "melphalan",
            "description": {
                "common": "vitamin A, melphalan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "vitamin A, mercaptopurine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline, vitamin A. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of benign intracranial hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nelarabine",
            "description": {
                "common": "vitamin A, nelarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. (Vitamin A)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "vitamin A, oxaliplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "vitamin A, paclitaxel. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "vitamin A, paclitaxel protein bound. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentostatin",
            "description": {
                "common": "vitamin A, pentostatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "vitamin A, pralatrexate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptozocin",
            "description": {
                "common": "vitamin A, streptozocin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioguanine",
            "description": {
                "common": "vitamin A, thioguanine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiotepa",
            "description": {
                "common": "vitamin A, thiotepa. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topotecan",
            "description": {
                "common": "vitamin A, topotecan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treosulfan",
            "description": {
                "common": "vitamin A, treosulfan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinblastine",
            "description": {
                "common": "vitamin A, vinblastine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine",
            "description": {
                "common": "vitamin A, vincristine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "vitamin A, vincristine liposomal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "vitamin A, vinorelbine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Anaphylaxsis",
            "percent": null
        },
        {
            "name": "death after IV use",
            "percent": null
        },
        {
            "name": "Facial dermatitis",
            "percent": null
        },
        {
            "name": "Stratum corneum fragility",
            "percent": null
        },
        {
            "name": "Conjunctivities",
            "percent": null
        },
        {
            "name": "Sticky skin",
            "percent": null
        },
        {
            "name": "Granuloma",
            "percent": null
        },
        {
            "name": "like lesions in acne",
            "percent": null
        },
        {
            "name": "Dry mucus",
            "percent": null
        },
        {
            "name": "Paranochia",
            "percent": null
        },
        {
            "name": "Corneal opacities",
            "percent": null
        },
        {
            "name": "Palmoplanar peeling",
            "percent": null
        },
        {
            "name": "Cheilitis",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        }
    ]
}